This is the authors' abstract. We don't add key points for this paper.
Lapatinib (LAP), a dual inhibitor targeting ErbB1 and ErbB2 tyrosine kinases, demonstrates efficacy in treating ErbB2-positive breast cancer. However, its clinical use is hindered by the occurrence of associated diarrhoea. ErbB1 is expressed in the intestine; leading to the hypothesis that lapatinib inhibits normal ErbB1 function, causing diarrhoea. This study explores the potential role of ErbB1 inhibition in the mechanism of lapatinib-induced diarrhoea. Caco-2 intestinal monolayers were treated with LAP alone and in combination with recombinant epidermal growth factor (LAP+rEGF). The integrity of the Caco-2 monolayer was evaluated by measuring transepithelial electrical resistance (TEER) of the Caco-2 monolayer and Lucifer yellow paracellular transport. Changes in tight junction proteins (TJPs) claudin-1, occludin and ZO-1 were assessed through qPCR and immunofluorescence staining, while the expression levels of inflammatory cytokines TNF-α, IL-1β, and IL-6 were determined using qPCR. At 96 hours, LAP treatment resulted in a significant reduction in TEER compared to the untreated control monolayer (p < 0.05). Although not significantly different from the control group, the LAP group exhibited higher Lucifer yellow permeability. LAP suppressed mRNA and protein expression of TJPs, with cotreatment of rEGF mitigating LAP inhibition significantly (p < 0.05). No significant changes were observed in the mRNA expression levels of inflammatory cytokines in the LAP group. However, treatment with rEGF increased IL-6 mRNA expression significantly (p < 0.01). Lapatinib increased Caco-2 intestinal monolayer permeability and reduced tight junctions by inhibiting ErbB1, suggesting a mechanism of lapatinib-induced diarrhoea.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Sharin et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: